2. Project OverviewTo achieve the project goal of 160 million treatments to 40 million people in 15 countries overfive years, <strong>RTI</strong> worked to establish grants and coordination mechanisms for a team of NGOs(non-governmental organizations) and implementing partners to support integrated NTDcontrol <strong>program</strong>s organized and led by the governments of selected countries. The projectwas intended to build on existing commitments by governments and other donors, and tofill financial and technical gaps that were preventing national <strong>program</strong>s from reaching fullnational scale. The project followed four main principles:• Support and empower national governments to develop integrated NTD control <strong>program</strong>s embedded, where possible,within existing service delivery platforms and to lead these <strong>program</strong>s in scaling-up activities to full national levels;• Provide technical assistance for planning, budgeting, reporting and complying with international standards and guidelines toimprove <strong>program</strong> integration;• Promote cost-efficiency, improved integration strategies and effective advocacy;• Assure national ownership, continued commitment and resource mobilization for sustained support for NTD control 5 .Due to the overwhelming success of the approach, the NTDCP surpassed life of project targets in Year 3.5. Linehan M , Hanson C, Weaver A, Baker M, Kabore A, Zoerhoff K, Sankara D, Torres S, Ottesen E., Integrated Implementation of Programs Targeting <strong>Neglected</strong> TropicalDiseases through Preventive Chemotherapy: Proving the Feasibility at National Scale. Am. J. Trop. Med. Hyg., 84(1), 2011, pp. 5–1412<strong>Neglected</strong> Tropical Disease Control Program Final Report
2.1. Countries Supported by NTDCPThe <strong>program</strong> began working with five “fast track” countries in Africa: Burkina Faso, Ghana, Mali, Niger, and Uganda. Thesecountries were designated as “fast track” because they had already made a strong start toward control of NTDs under a pilotproject funded by the Bill and Melinda Gates Foundation and others. Each had unacceptably high burdens of NTDs and geographicoverlap of multiple NTDs, and each had demonstrated the flexibility and political will to integrate existing vertical <strong>program</strong>s. Thesecountries had all identified NTDs as a priority in a national health plan and would commit resources from a national budget.Importantly, the Ministries of Health, with support from this project, would have the capacity and ability to reach at least 2 to 3million people per year in each country.As additional resources became available over the life of the project, the NTDCP rapidly expanded beyond these initial 5 countries.In total, support for MDAs and overall NTD <strong>program</strong> implementation was provided in 13 countries: Burkina Faso, Cameroon,Ghana, Haiti, Indonesia, Mali, Nepal, Niger, Sierra Leone, South Sudan, Tanzania, Togo, and Uganda. Limited assistance wasprovided in an additional six countries: Bangladesh, Guinea, Mozambique, Philippines, Senegal, and Vietnam.2.2 USAID’s Largest Public-Private PartnershipCritical to NTDCP success was the commitment of the drug donation <strong>program</strong>s. The Mectizan Donation Program, ChildrenWithout Worms and <strong>International</strong> Trachoma Initiative together with their pharmaceutical partners, Merck & Co. Inc, GSK, Johnson& Johnson and Pfizer were dedicated to meet the demands of national NTD <strong>program</strong>s as they expanded to national scale. In thefirst year of the project, drug donation <strong>program</strong>s supplied over 36 million tablets of NTD drugs. By Year 5, this had dramaticallyincreased to over 200 million tablets. In total, over $US 3 billion in medicines were donated to country <strong>program</strong>s working with theNTDCP over the life of the project.USAID NTD PROGRAM SCALE-UP MATCHED BY DRUG DONATION PROGRAMSUSAID NTD Program Scale-up Matched by Drug Donation ProgramsTreatment with ZithromaxTreatment with Zithromax, Mectizan, ® , MectizanAlbendazole, ® , albendazole, mebendazole, praziquantel, and diethylcarbamazine.Mebendazole, Praziquantel, and DEC.1000$949m25# of treatments and drug value, in millions800600400200036.8$404m58$507m130.6$577m160.7$686m208.1FY 07 08 09 10 11Burkina Faso, Ghana, Niger, Sierra Leone, Togo transitioned from NTDCP to the END in Africaproject before the close of the NTDCP. USAID assistance through NTDCP ended in FY11.20151050total # of countries13Treatments Provided inUSAID supported countriesValue of drug donations deliveredto NTDCP countries<strong>Neglected</strong> Tropical Disease Control Program Final ReportNumber of Countries